Plant production of recombinant antigens containing the receptor binding domain (RBD) of two SARS-CoV-2 variants
Biotechnology Letters · 2024
DOI: 10.1007/s10529-024-03517-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology Letters, 2024. Verfasst von Flavia Fagiani und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Biotechnology, ENEA Research Center Casaccia, 00123, Rome, Italy. Hauptthemen laut MEDLINE: Nicotiana, Spike Glycoprotein, Coronavirus, SARS-CoV-2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Ministero dell'Istruzione, dell'Università e della Ricerca, Ministero dell’Istruzione, dell’Università e della Ricerca.
Abstract (Originalsprache)
OBJECTIVES: The aim of this work was to rapidly produce in plats two recombinant antigens (RBDw-Fc and RBDo-Fc) containing the receptor binding domain (RBD) of the spike (S) protein from SARS-CoV-2 variants Wuhan and Omicron as fusion proteins to the Fc portion of a murine IgG2a antibody constant region (Fc). RESULTS: The two recombinant antigens were expressed in Nicotiana benthamiana plants, engineered to avoid the addition of N-linked plant-typical sugars, through vacuum agroinfiltration and showed comparable purification yields (about 35 mg/kg leaf fresh weight). CONCLUSIONS: Their Western blotting and Coomassie staining evidenced the occurrence of major in planta proteolysis in the region between the RBD and Fc, which was particularly evident in RBDw-Fc, the only antigen bearing the HRV 3C cysteine protease recognition site. The two RBD N-linked glycosylation sites showed very homogeneous profiles free from plant-typical sugars, with the most abundant glycoform represented by the complex sugar GlcNAc4Man3. Both antigens were specifically recognised in Western Blot analysis by the anti-SARS-CoV-2 human neutralizing monoclonal antibody J08-MUT and RBDw-Fc was successfully used in competitive ELISA experiments for binding to the angiotensin-converting enzyme 2 receptor to verify the neutralizing capacity of the serum from vaccinated patients. Both SARS-Cov-2 antigens fused to a murine Fc region were rapidly and functionally produced in plants with potential applications in diagnostics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Biotechnology, ENEA Research Center Casaccia, 00123, Rome, Italy.
- Proteomics, Metabolomics & Mass Spectrometry Laboratory, ISPAAM, National Research Council, 80055, Portici, Italy.
- Laboratory of Biotechnology, ENEA Research Center Casaccia, 00123, Rome, Italy. Carla.marusic@enea.it.
- Laboratory of Biotechnology, ENEA Research Center Casaccia, 00123, Rome, Italy. marcello.donini@enea.it.
Förderung
- Ministero dell'Istruzione, dell'Università e della Ricerca
- Ministero dell’Istruzione, dell’Università e della Ricerca
Zitieren
APA
Fagiani, F., Frigerio, R., Salzano, A. M., Scaloni, A., Marusic, C., & Donini, M. (2024). Plant production of recombinant antigens containing the receptor binding domain (RBD) of two SARS-CoV-2 variants. Biotechnology Letters. https://doi.org/10.1007/s10529-024-03517-9
Vancouver
Fagiani F, Frigerio R, Salzano AM, Scaloni A, Marusic C, Donini M. Plant production of recombinant antigens containing the receptor binding domain (RBD) of two SARS-CoV-2 variants. Biotechnology Letters. 2024. doi:10.1007/s10529-024-03517-9
BibTeX
@article{Fagiani2024,
author = {Fagiani, Flavia and Frigerio, Rachele and Salzano, Anna Maria and Scaloni, Andrea and Marusic, Carla and Donini, Marcello},
title = {Plant production of recombinant antigens containing the receptor binding domain (RBD) of two SARS-CoV-2 variants},
journal = {Biotechnology Letters},
year = {2024},
doi = {10.1007/s10529-024-03517-9}
}
EUVIMED